Cargando…
Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice
Peptide hormone-based targeted therapy to tumors has been studied extensively. Our previous study shows that somatostatin receptor expresses high level on drug-resistant human ovarian cancer. The paclitaxel-octreotide conjugate (POC) exhibits enhanced growth inhibition, as well as reduced toxicity,...
Autores principales: | Chen, Xi, Zhang, Xiao-Yu, Shen, Yang, Fan, Li-Li, Ren, Mu-Lan, Wu, Yong-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347781/ https://www.ncbi.nlm.nih.gov/pubmed/27825139 http://dx.doi.org/10.18632/oncotarget.13120 |
Ejemplares similares
-
Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells
por: Fan, Li-li, et al.
Publicado: (2020) -
Cajanol Sensitizes A2780/Taxol Cells to Paclitaxel by Inhibiting the PI3K/Akt/NF-κB Signaling Pathway
por: Sui, Ming, et al.
Publicado: (2021) -
How Taxol/paclitaxel kills cancer cells
por: Weaver, Beth A.
Publicado: (2014) -
Breaking malignant nuclei as a non-mitotic mechanism of taxol/paclitaxel
por: Smith, Elizabeth R., et al.
Publicado: (2021) -
Targeted paclitaxel‐octreotide conjugates inhibited the growth of paclitaxel‐resistant human non‐small cell lung cancer A549 cells in vitro
por: Liu, Yanguo, et al.
Publicado: (2021)